NFE2L2 and early-onset autosomal dominant Alzheimer disease: In addition, many drugs that can be used to treat Alzheimer’s disease by activating NRF2, such as resveratrol, pyridoxine, and NBP (n-butylphthalide), have also entered clinical trials.